The estimated Net Worth of Kurt R Widmer is at least $13 Milione dollars as of 10 January 2014. Kurt Widmer owns over 89,589 units of Hookipa Pharma Inc stock worth over $6,871,466 and over the last 16 years Kurt sold HOOK stock worth over $6,092,729.
Kurt has made over 28 trades of the Hookipa Pharma Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Kurt sold 89,589 units of HOOK stock worth $1,523,013 on 10 January 2014.
The largest trade Kurt's ever made was selling 100,000 units of Hookipa Pharma Inc stock on 30 August 2013 worth over $1,200,000. On average, Kurt trades about 18,655 units every 39 days since 2008. As of 10 January 2014 Kurt still owns at least 1,301,414 units of Hookipa Pharma Inc stock.
You can see the complete history of Kurt Widmer stock trades at the bottom of the page.
Kurt's mailing address filed with the SEC is 929 NORTH RUSSELL STREET, , PORTLAND, OR, 97227.
Over the last 21 years, insiders at Hookipa Pharma Inc have traded over $12,222,300 worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth $18,573,557 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... e Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of $180,581. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth $5,110.
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Hookipa Pharma Inc executives and other stock owners filed with the SEC include: